



PSORIASIS

SUCCESSFUL TREATMENT OF PUSTULAR PSORIASIS WITH ITOLIZUMAB A NOVEL CD6 BLOCKING ANTIBODY IN 3 CASES.

Mahendra Kura⁽¹⁾ - Avinash Sajgane⁽¹⁾ - Maina Hegde⁽¹⁾

Grant Government Medical College & J J Hospital, Dermatology, Venereology And Leprosy, Mumbai, India⁽¹⁾

Background : Pustular psoriasis remains a challenge for management to the clinician in view of its chronic relapsing nature that often takes severe forms in view of paucity of specific treatment options. Itolizumab a humanized anti CD6 monoclonal antibody that acts by modulating the CD6 molecule required for T cell stimulation has been used successfully in psoriasis vulgaris. In view of lack of proven effective therapy options in pustular psoriasis Itolizumab offers an area of exploration for its utility.

Observation: Three patients of generalised pustular psoriasis all females aged 12, 35 and 53 respectively failing conventional immunosuppressive therapy / retinoids were admitted and investigated thoroughly. Pustular psoriasis disease severity was assessed with pustular symptom score and photographs. All patients were treated with injection Itolizumab 1.6 mg/kg / dose 2 weekly for 12 weeks followed by every 4 weekly for 12 weeks (Total 10 doses). Patients are being followed up for relapses. All three patients showed significant resolution of the skin lesions with few adverse effects. Nail and flexural lesions showed persistent disease activity.

Key message : Itolizumab an anti CD6 monoclonal antibody is a new avenue to explore further in the treatment of pustular psoriasis a disabling entity.

